Open Actively Recruiting

Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

About

Brief Summary

The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.

Primary Purpose
The main objective of the intervention(s) being evaluated by the clinical trial. Learn more
Treatment
Study Type
The nature of the investigation or investigational use for which clinical study information is being submitted. Learn more
Interventional
Phase
Phase 3

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
1 Day
Maximum Age
5 Days

Inclusion Criteria:

  • Male or female pre-term infant 26 and up to 32 weeks gestation. Gestational age matching (±2 weeks) between maternal dates and/or early antenatal ultrasound
  • Birth weight ≥ 500g
  • Singleton or twin birth

Exclusion Criteria:

-

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Pre-Screen Now
Call Me Back
855-731-6040
Study Stats
Protocol No.
25-2312
Category
GI Disorders
Pediatric Disorders
Principal Investigator
Kara L. Calkins, MD
Kara L. Calkins, MD
Neonatology
Contact
  • Ashley Dong
Location
  • UCLA Santa Monica
  • UCLA Westwood
For Providers
NCT No.
NCT05670951
For detailed technical eligibility, visit ClinicalTrials.gov.